The Claim
Monoclonal antibodies targeting PCSK9, including alirocumab and evolocumab, reduce plasma LDL-cholesterol levels by approximately 60% through binding to circulating PCSK9 outside hepatocytes, thereby preventing its interaction with the LDL receptor, which enhances LDL clearance and lowers cardiovascular risk in high-risk patients.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
These special lab-made antibodies grab onto a protein in your blood that messes with cholesterol cleanup, so your body can get rid of bad cholesterol better and lower your chances of heart problems.
See the scientific wording
Monoclonal antibodies targeting PCSK9, such as alirocumab and evolocumab, reduce plasma LDL-cholesterol levels by approximately 60% by binding circulating PCSK9 outside hepatocytes, preventing its interaction with the LDL receptor, which enhances LDL clearance and lowers cardiovascular risk in high-risk patients.
What the research says
1 studyStudy: Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?
The study looks at the same cholesterol-lowering drugs mentioned in the claim and finds they work just as described, lowering bad cholesterol by about 60%.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.